

ALESSANDRA POMPA

WORK HISTORY

- **MEDICAL DOCTOR** 09/2014 to Current
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
- **MEDICAL RESIDENT** 06/2010 to 06/2014
IRCCS Policlinico San Matteo, Pavia, Italy
- **MEDICAL RESIDENT** 06/2009 to 06/2010
Ospedale Spirito Santo, Pescara, Italy

EDUCATION

- **University of Pavia**, Pavia
Specialization in Hematology, 2014
- **University of Chieti**, Chieti
M.D., Degree in Medicine And Surgery, 10/2008
- **ICH- GCP training**, 03/2022

EXPERIENCE

- Principal and co-investigator in numerous clinical trials, principally involving multiple myeloma

REFERENCES

- Terpos E, Dimopoulos MA, Boccadoro M, et al. Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial [published online ahead of print, 2022 Jan 28]. Am J Hematol. 2022;10.1002/ajh.26480. doi:10.1002/ajh.26480
- Dimopoulos MA, Schjesvold F, Doronin V, et al. Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase II trial. Blood Cancer J. 2022;12(1):9. Published 2022 Jan 24. doi:10.1038/s41408-021-00593-2
- Ziccheddu B, Da Via MC, Lionetti M, Maeda A, Morlupi S, Dugo M, Todoerti K, Oliva S, D'Agostino M, Corradini P, Landgren O, Iorio F, Pettine L, Pompa A, Manzoni M, Baldini L, Neri A, Maura F, Bolli N. Functional impact of genomic complexity on the transcriptome of Multiple Myeloma. Clin Cancer Res. 2021 Sep 15;clincanres.4366.2020. doi: 10.1158/1078-0432.CCR-20-4366. Epub ahead of print. PMID: 34526359.
- Pompa A, Pettine L, Giannarelli D, Paris L, Torretta L, Cavallaro F, Levati GV, Stefanoni P, Mocellin C, Galli M, Baldini L. Safety of outpatient stem cell mobilization with low- or intermediate-dose cyclophosphamide in newly diagnosed multiple myeloma patients. Eur J Haematol. 2021 Jul 23. doi: 10.1111/ejh.13693. Epub ahead of print. PMID: 34297879.

- Peri AM, Cagliani R, Bozzi G, Pompa A, Manganaro L, Baldini L, Gori A, Bandera A. Chromosomally integrated human herpesvirus 6 (ci-HHV-6) in autologous bone marrow transplant recipients: are we missing a reactivation or is it just mimicking? *J Clin Virol*. 2021 Jun;139:104823. doi: 10.1016/j.jcv.2021.104823. Epub 2021 Apr 16. PMID: 33910132.
- Larocca A, Bonello F, Gaidano G, D'Agostino M, Offidani M, Cascavilla N, Capra A, Benevolo G, Tosi P, Galli M, Marasca R, Giuliani N, Bernardini A, Antonioli E, Rota-Scalabrini D, Cellini C, Pompa A, Monaco F, Patriarca F, Caravita di Toritto T, Corradini P, Tacchetti P, Boccadoro M, Bringhen S. Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. *Blood*. 2021 Jun 3;137(22):3027-3036. doi: 10.1182/blood.2020009507. PMID: 33739404.
- Manzoni M, Pompa A, Fabris S, Pelizzoni F, Ciceri G, Seia M, Ziccheddu B, Bolli N, Corradini P, Baldini L, Neri A, Lionetti M. Limits and Applications of Genomic Analysis of Circulating Tumor DNA as a Liquid Biopsy in Asymptomatic Forms of Multiple Myeloma. *Hemasphere*. 2020 Jun 29;4(4):e402. doi: 10.1097/HS9.0000000000000402. PMID: 32903996; PMCID: PMC7448367.
- Fattizzo B, Giannotta JA, Barcellini W, Barbanti MC, Bucelli C, Cassin R, Cattaneo D, Cavallaro F, Ferla V, Fracchiolla NS, Freyrie A, Galassi G, Goldaniga MC, Grifoni FI, Iurlo A, Mangiameli G, Mattiello V, Meli M, Neri A, Noto A, Onida F, Ottani L, Pasquale R, Pettine L, Pompa A, Reda G, Rossi FG, Saporiti GN, Sciumè M, Tagliaferri E, Baldini L. Ensuring continuity of care of hematologic patients during COVID-19 pandemic in a tertiary hospital in Lombardy (Italy). *Blood Adv*. 2020 Jul 14;4(13):2996-2999. doi: 10.1182/bloodadvances.2020002120. PMID: 32609844; PMCID: PMC7362383.
- Manzoni M, Marchica V, Storti P, Ziccheddu B, Sammarelli G, Todaro G, Pelizzoni F, Salerio S, Notarfranchi L, Pompa A, Baldini L, Bolli N, Neri A, Giuliani N, Lionetti M. Application of Next-Generation Sequencing for the Genomic Characterization of Patients with Smoldering Myeloma. *Cancers (Basel)*. 2020 May 23;12(5):1332. doi: 10.3390/cancers12051332. PMID: 32456143; PMCID: PMC7281620.
- Gentile M, Specchia G, Derudas D, Galli M, Botta C, Rocco S, Conticello C, Califano C, Giuliani N, Mangiacavalli S, Attingenti E, Lombardo A, Brunori M, Rossi E, Antonioli E, Ria R, Zambello R, Di Renzo N, Mele G, Marcacci G, Musto P, Capalbo S, Cascavilla N, Cerchione C, Belotti A, Criscuolo C, Uccello G, Curci P, Vigna E, Fraticelli V, Vincelli D, Bonalumi A, Siniscalchi A, Stocchi R, Martino M, Ballanti S, Gangemi D, Gagliardi A, Gamberi B, Pompa A, Recchia AG, Tripepi G, Pitino A, Frigeri F, Consoli U, Bringhen S, Zamagni E, Patriarca F, De Stefano V, Di Raimondo F, Palmieri S, Petrucci MT, Offidani M, Boccadoro M, Cavo M, Morabito F. Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials. *Haematologica*. 2021 Jan 1;106(1):291-294. doi: 10.3324/haematol.2019.241513. PMID: 32107338; PMCID: PMC7776255.
- Smoldering multiple myeloma: the role of different scoring systems in identifying high-risk patients in real-life practice. Cocito F, Mangiacavalli S, Valeria Ferretti V, Cartia CS, Ganzetti M, Benvenuti P, Pompa A, Catalano M, Fugazza E, Landini B, Arcaini L, Corso A. *Leuk Lymphoma*. 2019 Jun 6:1-7. doi: 10.1080/10428194.2019.1620948. [Epub ahead of print] PMID: 31169049
- Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma. Loglio A, Viganò M, Grossi G, Labanca S, Goldaniga M, Pompa A, Farina L, Rumi M, Corradini P, Facchetti F, Lunghi G, Baldini L, Lampertico P. *Dig Liver Dis*. 2019 Mar;51(3):419-424. doi: 10.1016/j.dld.2018.08.024. Epub 2018 Sep 7. PMID: 30316785
- Global methylation patterns in primary plasma cell leukemia. Todoerti K, Calice G, Trino S, Simeon V, Lionetti M, Manzoni M, Fabris S, Barbieri M, Pompa A, Baldini L, Bollati V, Zoppoli P, Neri A, Musto P. *Leuk Res*. 2018 Oct;73:95-102. doi: 10.1016/j.leukres.2018.09.007. Epub 2018 Sep 18. PMID: 30257227
- Gerber B, Manzoni M, Spina V, Brusca G, Lionetti M, Fabris S, Barbieri M, Ciceri G, Pompa A, Forestieri G, Lerch E, Servida P, Bertoni F, Zucca E, Ghielmini M, Cortelezzi A, Cavalli F, Stussi G, Baldini L, Rossi D, Neri A. Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias. *Haematologica*. 2018 Feb 22. pii: haematol.2017.184358. doi: 10.3324/haematol.2017.184358. [Epub ahead of print]

- Neri A, Todoerti K, Lionetti M, Simeon V, Barbieri M, Nozza F, Vona G, Pompa A, Baldini L, Musto P. Primary plasma cell leukemia 2.0: advances in biology and clinical management. *Expert Rev Hematol* 2016;9:1063-1073
- Mangiacavalli S, Pompa A, Ferretti V, Klersy C, Cocito F, Varettoni M, Cartia CS, Cazzola M, Corso A. The possible role of burden of therapy on the risk of myeloma extramedullary spread. *Ann Hematol* 2017;96:73-80.
- Romano A, Parrinello NL, Consoli ML, Marchionni L, Forte S, Conticello C, Pompa A, Corso A, Milone G, Di Raimondo F, Borrello I. Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents. *Ann Hematol* 2015;94:1875-83.
- Cocito F, Ricciardelli G, Mangiacavalli S, Pompa A, Pochintesta L, Ferretti V, Ceccuzzi R, Cazzola M, Bianchi PE, Corso A. Corneal sub-basal neural damage pattern in multiple myeloma patients treated with bortezomib: an in vivo confocal study. *Leuk Lymphoma* 2015;56:3440-1.
- Abeni MS, Magni M, Conte M, Mangiacavalli S, Pochintesta L, Vicenzi G, Ferretti VV, Pompa A, Cocito F, Klersy C, Corso A. Psychological care of caregivers, nurses and physicians: a study of a new approach. *Cancer Med* 2014;3:101-10
- Corso A, Mangiacavalli S, Cocito F, Pascutto C, Ferretti VV, Pompa A, Ciampichini R, Pochintesta L, Mantovani LG. Long term evaluation of the impact of autologous peripheral blood stem cell transplantation in multiple myeloma: a cost-effectiveness analysis. *PLoS One* 2013;8:e75047.
- Pochintesta L, Mangiacavalli S, Cocito F, Pompa A, Albertini R, Pascutto C, Ferretti VV, Cazzola M, Corso A. Serum C terminal telopeptide maintains its correlation with bone disease in patients with myeloma even under treatment with bisphosphonates. *Leuk Lymphoma* 2013 [Epub ahead of print].
- Mangiacavalli S, Cocito F, Pochintesta L, Pascutto C, Ferretti V, Varettoni M, Zappasodi P, Pompa A, Landini B, Cazzola M, Corso A. Monoclonal gammopathy of undetermined significance: a new proposal of workup. *Eur J Haematol.* 2013;91:356.
- Mangiacavalli S, Pochintesta L, Cocito F, Pompa A, Bernasconi P, Cazzola M, Corso A. Correlation between burden of 17P13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma. *Br J Haematol.* 2013;162:555.
- Mangiacavalli S, Pochintesta L, Pascutto C, Cocito F, Pompa A, Cazzola M, Corso A. Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma. *Am J Hematol.* 2013;88:102.
- Quaglietta A, Nicolucci A, Accorsi P, Pompa A, Pierelli L, Iacone A. Survey of current practice for monitoring and management of platelet refractoriness in Italy. *Transfus Apher Sci.* 2012;47:271

I authorize the processing of my personal data pursuant to art. 13 d. lgs. June 30, 2003 No. 196 – "Regulation on the protection of personal data" and Article. 13 GDPR 679/16 - "European regulation on the protection of personal data".

Milan, March 2022

Alessandra Pompa